Coverage
-
March 27, 2013
A California federal judge on Wednesday refused to reconsider her prior art invalidation of nine method claims regarding a DNA-sequencing method patent owned by Illumina Inc., ruling that the company didn't offer any new rationale since her invalidation ruling favoring competitor Complete Genomics Inc.
2 other articles on this case.
View all »